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ABSTRACT
Objective: To determine the cost-effectiveness of
salvage cryotherapy (SC) in men with radiation
recurrent prostate cancer (RRPC).
Design: Cost-utility analysis using decision analytic
modelling by a Markov model.
Setting and methods: Compared SC and androgen
deprivation therapy (ADT) in a cohort of patients with
RRPC (biopsy proven local recurrence, no evidence
of metastatic disease). A literature review captured
published data to inform the decision model, and
resource use data were from the Scottish Prostate
Cryotherapy Service. The model was run in monthly
cycles for RRPC men, mean age of 70 years. The
model was run over the patient lifetime, to assess
changes in patient health states and the associated
quality of life, survival and cost impacts. Results are
reported in terms of the discounted incremental
costs and discounted incremental quality-adjusted
life years (QALYs) gained between the 2 alternative
interventions. Probabilistic sensitivity analysis used a
10 000 iteration Monte Carlo simulation.
Results: SC has a high upfront treatment cost, but
delays the ongoing monthly cost of ADT. SC is the
dominant strategy over the patient lifetime; it is more
effective with an incremental 0.56 QALY gain (95% CI
0.28 to 0.87), and less costly with a reduced lifetime
cost of £29 719 (€37 619) (95% CI −51 985 to
−9243). For a ceiling ratio of £30 000, SC has a 100%
probability to be cost-effective. The cost neutral point
was at 3.5 years, when the upfront cost of SC (plus
any subsequent cumulative cost of side effects and
ADT) equates the cumulative cost in the ADT arm.
Limitations of our model may arise from its
insensitivity to parameter or structural uncertainty.
Conclusions: The platform for SC versus ADT cost-
effective analysis can be employed to evaluate other
treatment modalities or strategies in RRPC. SC is the
dominant strategy, costing less over a patient’s
lifetime with improvements in QALYs.
Trial registration number: This economic analysis
was undertaken as part of the CROP RCT study
ISRCTN:72677390; it was a pre-trial economic model
developed and analysed during the pre-results stage
of the RCT.
Strengths and limitations of this study
▪ Androgen deprivation therapy (ADT) is often
overutilised in patients who could be potential
candidates for salvage local therapy. We devel-
oped a decision model informed by the best
available evidence on the benefits, quality of life
and costs of treatment with salvage cryotherapy
(SC) and ADT to inform a cost-effectiveness ana-
lysis. We adhered to good practice guidelines
and the National Institute for Health and Care
Excellence (NICE) reference case, reporting out-
comes as discounted incremental cost per
quality-adjusted life year gained.
▪ To our knowledge, this is the first economic ana-
lysis comparing the use of SC against ADT. Several
evaluations have explored the cost-effectiveness of
ADT in advanced/metastatic prostate cancer, but
none in the radiation recurrent prostate cancer
(RRPC) population, and none on SC in RRPC.
▪ To date, there have been no direct head-to-head
comparisons of cryotherapy and ADT in a rando-
mised controlled trial; however, the outcomes
from published reports from multiple centres in
the USA and Europe justify the significance and
importance of cryotherapy as an alternative to
ADT in the RRPC population.
▪ This study found a lack of direct head-to-head
comparison data for use in the model, and there-
fore the main assumptions employed in the
model were conservative and used to work
against cryotherapy. The analysis was undertaken
using probabilistic sensitivity analysis to account
for uncertainty in the parameter inputs.
▪ Cryotherapy is an important local treatment
option for RRPC sufferers. The UK decision body
NICE drew attention to a lack of evidence on cryo-
therapy as a treatment for recurrent prostate
disease in 2008, and recommended it only be
used in clinical trials until further economic and
clinical evidence was established. Hence, the
methodology and data presented in this report are
of direct relevance to decision-making bodies.
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INTRODUCTION
Radiation recurrent prostate cancer (RRPC) is a well-
established global issue, yet receives little attention from
the research community and is supported by inadequate
data to inform evidence-based decisions.1 When consid-
ering a conservative estimate of 25% disease relapse
following primary radiation therapy, over 13 600 new
cases of RRPC are expected each year in the USA,2 with
approximately 81 000 across Europe.3 This translates
into a substantial ﬁnancial burden on healthcare ser-
vices, with the long-term cost of prostate cancer care
(diagnosis, treatment and follow-up) for 5 years in
European countries ranging from €198 million (Spain)
to €618 million (France).4 Given the scale of ﬁnancial
burden incurred by prostate cancer, a clear and robust
platform to evaluate the cost-effectiveness of current and
emerging treatment options is necessary.
Androgen deprivation therapy (ADT) is a palliative
treatment with well-documented side effects and health
risks.5 Deferred or immediate ADTremains the common-
est strategy used for RRPC sufferers6–8 and is often overu-
tilised in patients who could be potential candidates for
salvage local therapy. This reﬂects the lack of high-quality,
mature supportive evidence from prospective multicentre
studies on alternative treatments, including salvage
surgery (prostatectomy, cystoprostatectomy)9 10 and local
ablative approaches (cryotherapy, focal brachytherapy,
high-intensity focused ultrasound). Salvage prostate cryo-
therapy is a viable option with an acceptable efﬁcacy and
toxicity proﬁle.11–15 While the debate continues among
proponents of different RRPC therapies, cost-
effectiveness analyses are integral and essential to policy-
making considerations. We set out to develop a platform
for decision analytic cost-effectiveness evaluation by com-
paring ADT and salvage cryotherapy (SC) for patients
with RRPC.
MATERIALS AND METHODS
Decision analytic modelling was used to evaluate the
potential cost-effectiveness of SC in comparison to ADT
in the RRPC population (biopsy-proven local recurrence
with no evidence of metastatic disease).16 We adhered to
good practice guidelines and the National Institute for
Health and Care Excellence (NICE) reference case,17
reporting outcomes as discounted incremental cost per
quality-adjusted life year (QALY) gained (cost year 2014)
from the perspective of the UK National Health Service
(NHS). The UK decision threshold of £20 000–£30 000/
QALY will be used to determine cost-effectiveness.17 The
economic model was designed, developed and popu-
lated based on published literature and in accordance
with clinical practice. A literature review was undertaken
(MEDLINE, EMBASE, Cochrane Library—NHSEED,
HTA, DARE—and the CEA Registry from 1990 to
August 2014) to identify data on patient survival and
disease progression following ADT and SC in the RRPC
population. Economic evaluations of ADT or SC in this
patient group were also incorporated. Literature was
required to inform speciﬁc model parameters, such as
utility estimates for patient quality of life. Further details
of the literature search are available in the online
supplementary material. Estimates of resource use were
obtained from the Scottish Prostate Cryotherapy
Service18 and guided by clinical experts in the ﬁeld.
Unit costs were obtained from reference sources such as
the British National Formulary,19 Information Services
Division20 and the Department of Health21 (see online
supplementary information).
Model structure and parameters
Figure 1 details the alternative treatment strategies and
Markov model, with transition between states limited to
the direction illustrated by arrows. A patient entering the
model will have previously received primary radiotherapy
(either brachytherapy or external beam) for his prostate
cancer and subsequently developed biochemical relapse
with histologically conﬁrmed local recurrence without
detectable metastases.16 Importantly, he will be deemed
eligible for a randomised controlled trials (RCTs) as
described in ref. 16, thus providing a valid basis for com-
parison between different treatment options. Such a
patient can be treated with SC, ADT or a third strategy
where 80% of patients receive ADT immediately and 20%
have deferred ADT.6–8 It is unlikely that in practice, all
patients would immediately receive ADT, and therefore
this third strategy (ADTwith 20% deferred) was included
to reﬂect current practice.6–8 The Markov model com-
prises four states: ‘pre-ADT’ which for post-SC patients
is biochemical disease-free survival (BDFS), ‘BDFS
with ongoing ADT’, ‘Progression’ and ‘Death’.
Cryotherapy-associated adverse events (urinary incontin-
ence, obstructive urinary symptoms/retention, lower
urinary tract symptoms, perineal pain, haematuria, ureth-
ral stricture and ﬁstula) will typically manifest within
3 months post-treatment,22 and are assigned an add-
itional cost and quality of life decrement for this time
period. Patients with troublesome ADT-induced hot
ﬂushes may require additional antiandrogen treatment.
Patients who received SC will enter the Markov model
with the nadir prostate-speciﬁc antigen (nPSA) level
achieved, with nPSA <1 ng/mL being a good prognostic
marker.13 22 At the end of each monthly cycle, SC patients
can experience death, remain in the pre-ADT state or
develop biochemical recurrence13 triggering ﬁrst-line
ADT (with patients entering the lower BDFS state). In
the ADT arm, all patients enter the model in the BDFS
with ADT state, receiving monthly treatment with gosere-
lin as clinically recommended.8 23 The third strategy
accounts for a minority (20%) of patients who are
assumed to have deferred ADT;8 these patients enter the
model in the ‘pre-ADT’ state with a ‘do nothing’
approach to their biochemical recurrence. The remain-
ing 80% begin the Markov model in the BDFS with ADT
state. Here patients can experience death, remain stable
or experience disease progression with biochemical
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relapse +/− metastases. In the Progression state, 40% of
patients will have metastatic disease at any one time.24
Those patients in the Progression state will receive
second-line ADT as clinically indicated (monthly treat-
ment with abirateronei for metastatic progression, or with
leuprorelin acetate for non-metastatic progression).
The base-case model begins with a cohort of 1000
patients with RRPC (biopsy-proven local recurrence with
no evidence of metastatic disease)16 who have a mean
age of 70,13 14 and runs in monthly cycles for a time
horizon of 36 years (432 cycles), until everyone in the
cohort has died. This model is run for each of the treat-
ment groups using the intervention-speciﬁc costs,
disease-free survival (DFS) estimates, age-speciﬁc popula-
tion mortality rates and utility estimates, so as to calcu-
late total costs, life years gained (LYG) and QALY
outcomes for each treatment group. Costs and QALYs
were discounted at 3.5% as recommended for the NICE
reference case.17
Table 1 details the main parameters used in the
model, their SEs and the distribution used in the prob-
abilistic analysis. The resource use parameters, their SEs
and unit costs are detailed in table 2. The online supple-
mentary information document provides further details
of the Markov model, and online supplementary table
S2 details a summary of key model assumptions.
Uncertainty and sensitivity analyses
Probabilistic sensitivity analysis was undertaken using
Monte Carlo simulation (10 000 iterations) to reﬂect
uncertainty in the input parameter estimates.25 The
10 000 incremental cost and QALY outcomes are plotted
on a cost-effectiveness plane to illustrate uncertainty in
the model results. The cost-effectiveness acceptability
curve (CEAC) is presented to illustrate the probability of
each strategy being cost-effective at different willingness
to pay thresholds.
Five scenario analyses were undertaken to explore the
impact of varying some of the base-case assumptions.26
Scenario 1 explores the impact of abiraterone by assuming
this expensive treatment is not available for metastatic pro-
gression, instead all patients receive the much cheaper leu-
prorelin acetate treatment (£97 per month). Scenario 2
applies a greater relative risk of Progression from BDFS
with ADT for patients previously treated by cryotherapy.
This is a key uncertainty in the model as there have been
no RRPC trials directly comparing SC with ADT, and
therefore no evidence to suggest whether the risk of pro-
gression with ADT for postcryotherapy-relapsed disease
would be the same or greater when compared with
patients with RRPC receiving ADT without SC. Given this
uncertainty, the base-case analysis took a pessimistic
outlook for SC and applied a relative risk of 1.5; scenario 2
applies a greater relative risk of 2, increasing the hazard of
progression in the SC arm and ensuring that the pre-ADT
state in the model does not implicitly bias towards the SC
arm in terms of longevity. A third scenario used alternative
data15 for risk of recurrence following SC. In the ﬁnal two
scenarios, patient heterogeneity in the model was
explored by re-running the model for a mean patient age
of 60 and 80 years, respectively.
As detailed in the online supplementary information,
sensitivity analyses were also undertaken to ensure the
base-case spline distribution used for risk of recurrence
with SC was robust27 and the best ﬁt to the
Kaplan-Meier data.13
Figure 1 Alternative treatment
strategies and Markov model
(ADT, androgen deprivation
therapy; BDFS, biochemical
disease-free survival).
iEnzalutamide is an alternative to abiraterone, but the price and
duration difference between them is negligible, so substituting
abiraterone for enzalutamide in the model would not impact on the
costs or the outcomes.
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RESULTS
SC was on average £38 763 (€49 067) cheaper (95% CI
−63 535 to −16 175) than ADT and £29 719 (€37 619)
cheaper than the ADT 20% deferred strategy over a
patient’s lifetime, and was more effective with a mean
QALY gain of 0.68 (95% CI 0.4 to 1.04) and 0.56 (95%
CI 0.28 to 0.87), respectively (table 3A). There was little
difference in terms of life year gains between the strat-
egies, but when adjusted for quality of life, SC is clearly
the dominant strategy. The ADT immediate strategy is
dominated by both the SC and ADT 20% deferred strat-
egies, and as it is unlikely in practice that no patients
would have deferred treatment,8 the results and scenario
analysis will from now onwards compare SC to the ADT
20% deferred strategy.
Figure 2 plots the 10 000 incremental cost and QALY
outcomes from the probabilistic analysis on the cost-
effectiveness plane. All of the points fall in the south-
Table 1 Base-case model parameters
Parameter
Point
estimate SE
Probabilistic
distribution Data source
Mean age (years) 70 NA NA 13 and 14
Model lifetime (years) 36 NA NA 13 and 14
Discount rate (costs and outcomes) 0.035 NA NA 17
Proportion-confirmed metastases in progression 0.4 0.08 β AA24
Transition probabilities (monthly)
Cryotherapy to ADT Spline regression fitted to Kaplan
Meier DFS curve
13
Spline model hazard intercept −4.58 0.408 Normal Spline PH regression13
Spline model hazard s0 1.01 0.096 Normal Spline PH regression13
Spline model hazard s1 0.303 0.068 Normal Spline PH regression13
Deferred ADT to ADT 0.014 0.005 β 36
ADT to progression 0.016 0.004 β 36
Relative risk ADT to progression post-SC 1.5 1.38 Log normal AA
UK mortality rates: males, age specific 2010 UK interim life tables 40
Prostate cancer mortality: age specific 2010 UK prostate cancer mortality
rates
3
Adverse event probabilities
Fistula 0.05 0.010 β 22 33 and 35
Incontinence 0.12 0.024 β 22 33 and 35
Retention 0.07 0.014 β 22 33 and 35
Lower urinary tract symptoms 0.14 0.028 β 22 33 and 35
Perineal pain 0.04 0.008 β 22 33 and 35
Haematuria 0.05 0.01 β 22 33 and 35
Urethral stricture 0.10 0.02 β 22 33 and 35
Hot flushes 0.10 0.02 β Clinical expertise32
Cost
Cryotherapy* £8509 NA NA 18 and 20
First-line ADT per cycle* £83 NA NA 19
Second-line ADT per cycle*: confirmed
metastases†
£2930 NA NA 19
Second-line ADT per cycle*: non-metastatic† £95 NA NA 19
Fistula £4039 £808 γ 21
Incontinence £2170 £434 γ 21
Retention £3963 £793 γ 21
Lower urinary tract symptoms £10.47 NA NA 19
Perineal pain £5.16 NA NA 19
Haematuria 2445 £489 γ 21
Urethral stricture £3836 £767 γ 21
Hot flushes (per cycle) £5.54 NA NA 19
Utility
Disease-free survival 0.774 0.02 β 41
Progression: metastases 0.42 0.06 β 36 and 42
Progression: non-metastatic 0.68 0.022 β 41
Disutility for fistula 0.15 0.03 β AA/clinical experts
*Not probabilistic, but cost varies depending on probabilistic resource use parameters for delivery; see table 2.
†Depends on the proportion of patient in Progression state who have confirmed metastases.
ADT, androgen deprivation therapy; AA, author assumption made in conjunction with clinical experts; ICER, Incremental Cost-effectiveness
Ratio; PH, proportional hazards; SC, salvage cryotherapy.
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eastern quadrant, reinforcing SC as a dominant treat-
ment strategy for RRPC with cost-savings and improved
QALYs. There is little uncertainty in the cost-
effectiveness decision over a wider range of willingness
to pay thresholds, as demonstrated in the CEAC
(ﬁgure 3). Considering the NICE threshold of £30 000/
QALY,17 SC has a 100% probability to be cost-effective
(ﬁgure 3).
Although SC has an expensive upfront treatment cost
of £8509 (€10 771), by resetting the ‘PSA clock’, it
delays and may avoid the ongoing monthly treatment
with ADT. Figure 4 illustrates how the mean cost per
patient varies in each arm over time. The two curves
intersect at 3.5 years, which signiﬁes the cost neutral
point, where the upfront cost of SC (plus any subse-
quent cumulative cost of ADT) per person equates the
cumulative cost per person in the ADT arm.
Sensitivity analyses (table 3B) illustrate that the out-
comes remain mostly unchanged to modiﬁcations in key
model assumptions; and where outcomes do change,
Table 2 Costs: unit costs, resource use and total costs
Cost item
Unit
cost
Resource
use SE
Total
cost Source
Cryotherapy surgery
Ultrasound £47.84 1 NA £47.84 18 and 20
Surgeon time (consultant) £142.00 2.5 h 0.25* £355.00 20
Theatre (including staff, appliances, drugs, etc) £1125.00 2 h 0.2* £2250.00 20
Additional theatre cost(Argon, Helium, balloon and guidewire) £260.61 1 NA £260.61 18
Freezing needles (per kit including 2 freezing and 8 temp
needles)
£5052.17 1 kit NA £5052.17 18
Overnight stay in hospital £237.34 2 nights 0.2* £474.68 21
Catheter fitting and removal (40 min in total) £53.00 0.66 h 0.066* £35.33 20
£8475.64
Cryotherapy medication
Antibiotics: ciprofloxacin 10 tablets 250 mg twice daily×3 days £0.93 1 NA £0.93 18 and 19
Painkillers: acemetacin (Emflex) 60 mg, 90 capsule pack £28.20 1 NA £28.20 18 and 19
α-blockers: tamsulosin, 400 mg daily 30 tablet pack £4.42 1 NA £4.42 18 and 19
£33.75
Total cost per cryotherapy patient £8509.39
Cryotherapy acute adverse events
Incontinence: urinary incontinence with intermediate
complications
£2170 1 £434 £2170 20
Lower urinary tract symptoms: tamsulosin 30 tablets, 400 µg £10.47 1 NA £10.47 18 and 19
Perineal pain: ibuprofen 400 mg 30 tabs, 4× daily £3.61 1.42 NA £5.13 18 and 19
Haematuria: elective inpatient catheter £2445 1 £489 £2445 20
Urethral stricture: major open urethra procedure £3836 1 £767 £3836 20
Retention† £793 £3963 20
Fistula‡ £808 £4039 20
First-line ADT regime
Bicalutamide (10 days prior to LHRH—first month only) £5.54 1 NA £5.54 18 and 19
Goserelin: LHRH £65.00 1 NA £65.00 18 and 19
Bicalutamide (treatment for hot flush side effect) £5.54 0.1 NA £0.55 18
Delivery of goserelin (practice nurse) £53.00 0.33 h 0.066* £17.67 18 and 19
Total cost for first-line ADT first cycle £88.76
Total cost per first-line ADT cycle (every 28 days) £83.22
Second-line ADT (confirmed metastases)
Abiraterone tablets (monthly cost) £2930.00 1 NA £2930.00 19
Second-line ADT (rising PSA non-metastatic progression)
LHRH agonist: leuprorelin acetate £75.24 1 NA £75.24 18 and 19
Flutamide for proportion who have hot flush side effect £25.37 0.1 NA £2.54 18 and 19
Delivery (practice nurse) £53.00 0.33 h 0.066* £17.67 18 and 19
Total cost second-line ADT non-metastatic disease per cycle £95.44
Mean cost of second-line ADT in progression state per cycle§ £1229.27
Bold typeface indicates total costs for the main cost items.
*γ Distributions used for resource use parameters in the probabilistic analysis.21a
†Depends of proportion-confirmed metastases and non-confirmed. Base-case model 40% metastases (SE 0.08); see table 1.
‡Retention: elective inpatient catheter plus cost of transurethral resection of prostate for 50% of retention patients.
§Fistula: 4 hospital consultations, MRI plus 50% need colostomy or repair surgery.
ADT, androgen deprivation therapy; LHRH, luteinising hormone releasing hormone; PSA, prostate-specific antigen.
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Table 3 Results
Mean Inc cost Inc QALYs Probabilistic CE Cost neutral
Cost LYs QALYs (95% CI) (95% CI) ICER £30 000 Time point
(A) Base-case
Procedure
Cryotherapy (SC) £62 150 10.62 7.59 NA NA NA 1.0
ADT 20% deferred £91 869 10.58 7.03 £29 719 −0.56 SC dominates 0.0 3.5 years
(£9243 to £51 985) (−0.87 to −0.28)
ADT immediate £100 914 10.57 6.91 £38 763 −0.68 SC dominates 0.0 3 years
(£16 175 to £63 533) (−1.04 to −0.4)
(B) Scenario outcomes
Scenario
(1) No abiraterone ADT 20% £10 529 10.58 7.04 NA NA 0.0 Never
Low-cost second ADT SC £14 820 10.62 7.59 £4291 0.55 £7801 1.0 (>36 years)
(£1577 to £6253) (0.29 to 0.86)
(2) Relative risk=2 ADT 20% £91 894 10.58 7.02 NA NA 0.001 4 years
Progression post-SC SC £62 149 10.62 7.54 −£29 745 0.51 SC dominates 0.997
(−£53 847 to −£9320) (0.22 to 0.86)
(3) DFS data post-SC ADT 20% £91 959 10.58 7.03 NA NA 0.029 3.5 years
Wenske et al15 SC £62 156 10.63 7.66 −£29 803 0.63 SC dominates 0.971
(−£80 269 to £2597) (0.05 to 1.19)
(4) Mean age 60 years ADT 20% £142 629 14.49 9.40 NA NA 0.0 3.5 years
SC £93 410 14.53 10.18 −£49 219 0.77 SC dominates 1.0
(−£80 549 to −£22 615) (0.4 to 1.18)
(5) Mean age 80 years ADT 20% £46 997 6.67 4.58 NA NA 0.0 4 years
SC £32 362 6.70 4.90 −£14 635 0.33 SC dominates 1.0
(−£27 504 to −£7382) (0.17 to 0.51)
ADT, androgen deprivation therapy; CE, cost-effective; DFS, disease-free survival; Inc, incremental; LYs, life years; QALYs, quality-adjusted life years; SC, salvage cryotherapy.
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the cost-effectiveness decision remains in favour of cryo-
therapy. SC remains the dominant strategy under all but
scenario 1, with a 100% probability of being the cost-
effective strategy at a threshold of £30 000/QALY.
Scenario 1, which assumed a lower monthly cost for
second-line ADT (£95/month, no abiraterone for meta-
static treatment) resulted in the SC arm costing an add-
itional £4291 (€5432) over the patient lifetime, with a
QALY gain of 0.55. In this scenario, the model does not
reach a cost neutral point; however, the ICER of £7801/
QALY (€9875/QALY) is well below the UK decision
threshold of £20 000–£30 000/QALY.
DISCUSSION
We developed a decision model informed by the best
available evidence on the beneﬁts, quality of life and
costs of treatment with SC and ADT for patients with
RRPC. The model predicted that cryotherapy would be
cost-saving compared with ADT, and would offer
improvements in QALYs gained. Upfront treatment with
cryotherapy delayed, and in some cases avoided, subse-
quent treatment with ADT, giving a cost-neutral time of
3.5 years (the time it takes for a patient in the ADT arm
to equate the cost of a patient treated by SC).
Cryotherapy was found to be the dominant strategy over
a wide range of cost-effectiveness thresholds and under a
variety of scenario analyses.
The QALY decision threshold for cost-effectiveness is
subject to debate internationally and varies from country to
country;28–30 however, as shown in the CEAC in ﬁgure 3,
setting a lower, or higher threshold equivalent to US
$50 00029 or the €80 000 as suggested in the Netherlands,30
would not alter the conclusions of our analysis.
Several economic evaluations have been undertaken
to explore the cost-effectiveness of ADT in advanced/
Figure 2 Cost-effectiveness plane for SC compared with ADT 20% deferred (ADT, androgen deprivation therapy; QALYs,
quality-adjusted life years; SC, salvage cryotherapy).
Figure 3 Cost-effectiveness
acceptability curves for salvage
cryotherapy and androgen
deprivation therapy (ADT) 20%
deferred.
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metastatic prostate cancer, but none in the RRPC popu-
lation, and none on SC in RRPC (biopsy-proven local
recurrence with no evidence of metastatic disease); so to
our knowledge, this is the ﬁrst cost-utility analysis model-
ling and comparing the use of SC against ADT.
The literature search identiﬁed only nine papers11–14
31–35 detailing DFS evidence for SC in a RRPC popula-
tion. All were either retrospective analyses at clinical
urology units, online data registries or prospective case
studies, without a direct comparator or control. Given
this lack of evidence, we used DFS data from Williams
et al,13 which remains a landmark report for patient
outcome following SC with the longest follow-up cap-
tured in Kaplan-Meier curves for DFS. Previous cost-
effectiveness analyses in advance prostate cancer have
simply modelled progression as a constant hazard using
point estimates from published data to determine transi-
tion probabilities.36 Our analysis used Kaplan-Meier
data, and explored a variety of parametric distributions
to determine progression hazard for cryotherapy. It may
be argued that existing SC studies have been conducted
in highly select patient groups giving overoptimistic
results; therefore, our base-case model incorporated an
increased relative risk of progression from ADT for post-
cryotherapy patients, to counteract any ‘overoptimism’
for cryotherapy. Scenario 2 exaggerated this risk further,
but even so, SC remained cost-effective. Additionally,
scenario 3 used alternative data15 for the hazard of bio-
chemical relapse postcryotherapy. Even though there
has been no direct head-to-head comparisons of cryo-
therapy and ADT in the context of a RCT,16 the
outcome from published reports based on work in mul-
tiple centres in the USA and in Europe11–14 31–35 justify
the signiﬁcance and importance of cryotherapy as an
alternative to ADT in the RRPC population. ADT is
often overutilised in patients who could be potential
candidates for salvage local therapy or other (whole
gland or focal) ablative therapy, and therefore this
paper synthesises the existing evidence to provide neces-
sary information to inform a cost-effectiveness analysis.
The majority of assumptions employed in the model
were conservative and used to work against cryotherapy.
All assumptions have been fully described in the online
supplementary table S2, and have been applied based
on the best available evidence and in consultation with
clinical experts on the CROP trial team.16 Regardless of
the alternative assumptions or strategy employed, cryo-
therapy remained the cost-effective option.
The decision model in this paper has shown that
although cryotherapy has an expensive upfront treatment
cost, within 3.5 years the mean cost per patient is equiva-
lent to the mean cost of patients treated with ADTonly.
ADT has a much lower, yet ongoing, cost of approxi-
mately £83 (€105) per month (goserelin every 28 days)
which continues until a patient dies, or progresses and
then incurs the expensive second-line ADT regimen
(abiraterone for conﬁrmed metastases, leuprorelin for
non-conﬁrmed metastatic progression). Over the
remaining patient lifetime, the cost of ADT accumulates.
As patients in the SC arm only receive ﬁrst-line ADT on
biochemical recurrence following cryotherapy, this
further delays the need for second-line ADT when com-
pared with patients receiving ADT. It is this avoidance
and delay in both ﬁrst-line and second-line ADT that
leads to substantial cost-savings of approximately £29 719
(€37 619) per patient in the SC arm. Second-line ADT
treatment is signiﬁcantly more expensive than ﬁrst-line
ADT costing approximately £1229 (€1555) per patient
month (assuming 40% of patients are treated for con-
ﬁrmed metastatic progression24 with abiraterone at
£2930/month, and the remaining 60% for non-
metastatic progression at £95/month).
Scenario 1 showed that it is the high cost of abirater-
one which leads to the cost-saving advantages of SC in
the base-case model. When costly abiraterone treatment
is removed (scenario 1), SC is found to be more
Figure 4 Mean cost per patient over model lifetime (ADT, androgen deprivation therapy).
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expensive than the ADT 20% deferred strategy, but
would still be cost-effective with an ICER of £7801
(€9874).
The current clinical practice for patients with relapsed
disease following salvage prostate cryotherapy (and
indeed for any other local ablative therapy) is androgen
ablation therapy. For these patients, the treatment
pathway will mirror that of patients who receive ADT as
second-line treatment, without cryotherapy. Therefore,
treatment with ADT is the expected clinical patient
journey for patients failing cryotherapy. As the model
outcomes show, patients who receive cryotherapy will
essentially have their ‘PSA clock’ reset. A key issue from
this analysis is that the model identiﬁes the magnitude
of this ‘PSA clock’ reset required to adequately impact
on the cost-effectiveness of cryotherapy when compared
with the most commonly used treatment, that is, ADT. It
is also important to note that in terms of LYG, there is
little difference between SC, ADT and ADT 20%
deferred strategies. The advantage of SC appears to be
in delaying, and in some cases avoiding, progression of
disease, through resetting the ‘PSA clock’, which is par-
ticularly important in terms of metastatic progression
where patients are more likely to incur much higher
treatment costs and lower quality of life.
With regard to adverse events, previous studies of cryo-
therapy and ADT have found that short-term adverse
events have very little effect on overall/long-term quality
of life;37 however, they may incur considerable additional
costs in patient treatment, so it is important to capture
any cost or quality of life impacts of any acute adverse
events and how these may impact on model outcomes.
Therefore, the model allowed for patients in the SC
cohort to experience the seven most common
SC-related adverse events (incontinence, retention,
lower urinary tract symptoms, perineal pain, haematuria,
urethra stricture and ﬁstula), utilising the worst case esti-
mates reported in recent literature22 33 35 to ensure the
base-case analysis was pessimistic towards cryotherapy.
Persistent erectile dysfunction would be experienced by
the majority of patients who have RRPC before under-
taking cryotherapy or beginning ADT, as a result of
prior treatment,6 which is accounted for in the baseline
utility level for all cohorts (as detailed in online
supplementary material). While a small proportion of
patients may still be potent when entering the model,
and therefore have a slightly higher quality of life than
those who are impotent at baseline,38 the proportion of
patients with erectile dysfunction would be the same in
each arm of the cohort model, and therefore stratifying
the baseline population by impotence would not make
any difference to incremental gains and losses in QALY
outcomes. The age-adjusted utility value used for the
cohort population in each arm reﬂects a mid-way quality
of life point between potent patients and those suffering
from impotence. Tables 1 and 2 detail the probability
estimates and additional costs for treating SC-related
events (incontinence, retention, lower urinary tract
symptoms, perineal pain, haematuria, urethra stricture
and ﬁstula). Our model results are consistent with previ-
ous studies36 37 in that these acute SC-related adverse
events which are only experienced for the ﬁrst few
months have little impact on long-term quality of life
and QALY outcomes.36 37 The high upfront cost of treat-
ing these adverse events (see table 2) also has no signiﬁ-
cant impact in the longer term model outcomes for SC.
This is most likely due to (1) the relatively low incidence
of second surgical procedures in patients receiving SC
(see table 1) and (2) also because the cost of SC-related
adverse events are overshadowed by the lifetime cost-
savings and quality of life beneﬁts of SC through delay-
ing, and in some cases avoiding, progression of disease,
through resetting the ‘PSA clock’. As with all model-based
economic evaluations, a limitation of this analysis is that
the model and assumptions are based on retrospective
data, and therefore subject to the quality of this data.39 In
response to this limitation, the majority of assumptions
(see online supplementary table S2) employed in the
model were conservative and used to work against cryother-
apy. Cryotherapy is an important local treatment option for
RRPC sufferers. The UK decision body NICE drew atten-
tion to a lack of evidence on cryotherapy as a treatment for
recurrent prostate disease in 2008, and recommended it
only be used in clinical trials until further economic and
clinical evidence was established.8 Hence, methodology
and data presented in this report are of direct relevance to
decision-making bodies. This is particularly relevant as the
CROP RCT study (ISRCTN: 72677390, http://www.
controlled-trials.com/ISRCTN72677390)16 comparing
SC and androgen ablation has recently been stopped due
to patients declining randomisation opting for SC as a pre-
ferred treatment.
The intention of this model was to perform the cost-
effectiveness analysis on the most common treatment
options in RRPC. The platform developed in this paper
for SC versus ADT cost-effective analysis can be
employed to evaluate other treatment modalities or strat-
egies in RRPC. This paper will be critical to add to the
debate regarding overutilisation of ADT and underutil-
isation of salvage local therapy in the RRPC population,
and it is intended that this model can contribute to
future service planning for patients with RRPC.
Our report has synthesised the existing evidence in a
probabilistic analysis and shown that, despite a high
upfront treatment cost, SC substantially reduces the cost
of treating patients with RRPC over their lifetime by
delaying, and in some cases avoiding, ADT. We showed
that cryotherapy is a dominant treatment strategy when
compared with upfront ADT and should therefore be
reconsidered by decision-making bodies as a viable treat-
ment option for patients with RRPC.
CONCLUSION
SC is a dominant strategy in comparison to ADT, costing
less over a patient’s lifetime while offering improvements
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in QALYs. Probabilistic analysis (to account for uncer-
tainty in the model parameters) showed SC to be the
dominant strategy over a wide range of thresholds.
Under alternative model assumptions, the cost-
effectiveness decision remains in favour of cryotherapy.
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